



PTO/SB/08A/B (09-06)

Approved for use through 03/31/2007. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

| | | | | | |
|-------|---|----|---|------------------------|--------------|
| Sheet | 1 | of | 1 | Attorney Docket Number | 01017/40451B |
|-------|---|----|---|------------------------|--------------|

Complete if Known

| | |
|----------------------|------------------------|
| Application Number | 08/444,790-Conf. #5612 |
| Filing Date | May 19, 1995 |
| First Named Inventor | Manfred Brockhaus |
| Art Unit | 1646 |
| Examiner Name | Z. Howard |

U.S. PATENT DOCUMENTS

| Examiner Initials* | Cite No. ¹ | Document Number | Publication Date MM-DD-YYYY | Name of Patentee or Applicant of Cited Document | Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear |
|-----------------------|--------------------------|--|-----------------------------------|--|---|
| | | Number-Kind Code ² (if known) | | | |
| ZH | A64 | 5,428,130 | | | |
| ZH | A65 | 5,843,791 | | | |
| ZH | A66 | 6,224,867 | | | |

FOREIGN PATENT DOCUMENTS

| Examiner Initials* | Cite No. ¹ | Foreign Patent Document | Publication Date MM-DD-YYYY | Name of Patentee or Applicant of Cited Document | Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear | T ⁶ |
|-----------------------|--------------------------|---|-----------------------------------|--|---|----------------|
| | | Country Code ³ -Number ⁴ -Kind Code ⁵ (if known) | | | | |
| ZH | B42 | EP-0 394 827 | 10-31-1990 | | | |

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹ Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

NON PATENT LITERATURE DOCUMENTS


| Examiner Initials | Cite No. ¹ | Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published. | T ² |
|----------------------|--------------------------|---|----------------|
| ZH | C157 | FOLKS et al., Tumor necrosis factor α induces expression of human immunodeficiency virus in a chronically infected T-cell clone, PNAS, 86:2365-8 (1989). | |
| ZH | C158 | LEE, Generation of cDNA probes directed by amino acid sequence: cloning of urate oxidase, Science, 239:1288-1291 (1988). | |
| ZH | C159 | MORELAND et al., Treatment of rheumatoid arthritis with a recombinant human tumor necrosis factor receptor (p75)-Fc fusion protein, New England Journal of Medicine, 337:141-147 (1997). | |
| ZH | C160 | SANDBORN et al., Etanercept for active Crohn's disease: a randomized, double-blind, placebo-controlled trial, Gastroenterol., 121:1088-94 (2001). | |
| ZH | C161 | WOZNEY, Using purified protein to clone its genes, Methods in Enzymology, 182:738-751 (1990). | |
| ZH | C162 | Inflammation & Infection: Rheumatoid Arthritis, Drug & Market Development, 67-70 (2003). | |
| ZH | C163 | Letter to the EPO with new Auxiliary request 3 in appeal proc. against EP 0 471 701. | |
| ZH | C164 | Notification of the Examiner during the prosecution of EP 99100703.0. | |
| ZH | C165 | Zavoico, Drug & Market Development, 10(7):235-243 (1999). | |
| | | | |
| | | | |
| | | | |
| | | | |

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

| | | | |
|-----------------------|------------------|--------------------|------------|
| Examiner Signature | /Zachary Howard/ | Date Considered | 02/02/2007 |
|-----------------------|------------------|--------------------|------------|

957329



Approved for use through 07/31/2008. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

(Use as many sheets as necessary)

| | |
|------------------------|--------------|
| Application Number | 08/444,790 |
| Filing Date | May 19, 1995 |
| First Named Inventor | Brockhaus |
| Art Unit | 1646 |
| Examiner Name | Z. Howard |
| Attorney Docket Number | 01017/40451B |

| | | | |
|-------|---|----|---|
| Sheet | 1 | of | 2 |
|-------|---|----|---|

| | | | |
|-----------------------|------------------|--------------------|------------|
| Examiner Signature | /Zachary Howard/ | Date Considered | 02/02/2007 |
|-----------------------|------------------|--------------------|------------|

| | | | | | |
|---|---|----|---|--------------------------|--------------|
| Substitute for form 1449A/B/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(Use as many sheets as necessary)</i> | | | | Complete if Known | |
| | | | | Application Number | 08/444,790 |
| | | | | Filing Date | May 19, 1995 |
| | | | | First Named Inventor | Brockhaus |
| | | | | Art Unit | 1646 |
| | | | | Examiner Name | Z. Howard |
| Sheet | 2 | of | 2 | Attorney Docket Number | 01017/40451B |

| | | | | |
|----|------|--|--|--|
| ZH | C173 | Byrn et al., Biological properties of a CD4 Immunoaderhin, Nature, 344:667-670 (April 1990) | | |
| | C174 | Trauneeher et al., Highly Efficient Neutralization of HIV with Recombinant CD-4-Immunoglobulin Molecules, Nature 339:68-70, 1989 | | |
| | C175 | Capon, Designing CD4 Immunoaderhensions for AIDS Therapy, Nature, 337:525-531 (1989) | | |
| | C176 | Barone et al., Comparative Analysis of the Ability of Entanercept and Inflixamab to Lyse TNF-Expressing Cells in a Complement-Dependent fashion, Arthritis Rheum., v42(9) supplement, September 1999 | | |
| ↓ | C177 | Khare et al, Poster 715 presented at the Annual Meeting of the Society for Investigative Dermatology (SID), May 3-5, 2006, Philadelphia, PA | | |

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Applicant's unique citation designation number (optional). ²Applicant is to place a check mark here if English language Translation is attached.

| | | | |
|-----------------------|------------------|--------------------|------------|
| Examiner Signature | /Zachary Howard/ | Date Considered | 02/02/2007 |
|-----------------------|------------------|--------------------|------------|